Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't see how dilution can be over. How can they pay the new employees? With what revenue stream?
I see VNDM has been hanging higher on the ask, but maybe ARCA has been used to disguise some dilution?
Did you ever get updated numbers on Outstanding Shares?
Something to think about......
I know it has been mentioned before within other messages, but let's bring this to the forefront as a topic by itself.
Endonovo has no revenues.
Some executives have deferred salary for the benefit of keeping operation expense as low as possible.
So WHY have they added 2 new employees with the position titles of Investor Relations?????
WHY did they quietly open a Pittsburgh office?
SOMETHING is brewing behind the scenes and it HAS to be good. Only a matter of time before a PR gets released.
They are definitely preparing for something.
Get the shares now while they are on sale. SP this low will not be around much longer.
IMO
EVSV is too small to do a buyback of that proportion. They are too small to do any buyback. Trina will need all his spare cash for business expansion plans.
The only way to reduce O/S is reverse split. I would not want to be holding shares at that moment if it were to occur.
Seen to many panic sells after R/S.
There was actually a big selloff today..
Here is the location tied to the phone number of which Tami had a VM message identifying herself with Endonovo.
https://www.mapquest.com/us/pennsylvania/business-irwin/endonovo-therapeutics-inc-374178478
I believe your streak of bad luck will end with this stock.
The bad luck may only be selling too early, even after you are hundreds of percentage points in profit <grin>
You're right. We don't know since we are not communicated to by ENDV...hehe.
Looks like a viable possibility.
It looks like we could be getting very close to actual clinical trials.
Does anyone know of an approximate timeframe the actual clinicals would take to produce results?
Would it be faster than pre-clinicals since they should have the direct testing methods after "trials and errors" during the pre-clinicals?
Yep. I bought in at 2s hoping for a flip from the ER....nothing happened.....got out at 2s....only lost commission.
Looking for something with more potential without waiting forever.
I agree. It is too small of a business to really be a publicly traded company. And they have definitely benefited financially via the dilution of shares.
But...since it's legal...why not....hehe.
Investing in this company is a risk/reward that people have to make their own decisions on. And lessons to be learned. Just because it's super cheap to buy does not mean there is always upward potential. Could just trade sideways like it has for a long time.
Could be worse though. Reverse split and then dilute the shares again.
Cytotronics? What's that?
Has ENDV even mentioned that word this year? <grin>
Something else i forgot to mention....
Dr Leonard Makowka (Endonovo's Chief Medical Officer) had a brief stint as Professor @ Univ of Pitt. So he has some ties to the area as well....although that was in the early 80s.
It's something new we can chew on while the company remains silent with 3 Investor Relations employees now on the payroll.
I looked at the presenters for the upcoming Cardiology Conference in Philadelphia at the end of Aug. No presentations from anyone affiliated with UPMC unfortunately. Still too early to present our cutting edge technology.
And with more Form 4s posted today...no major material to be communicated in the upcoming days.
Closed at .0267....close to the .0269
At least it was a buy at closing.
Remember the game of someone always trying to paint it down at end of day? Nobody cares about that anymore.
All we want now is some positive communication from the company.
ENDV now has 3 Investor Relations employees and not 1 public communication since the Open Letter to Shareholders. What a head scratcher!!!
Nobody has called. We await your Monday update.
Will be interesting. VNDM has been sitting higher on ask. If we have had dilution, may be happening under ARCA.
Maybe they are hiding more dilution by using ARCA rather than VNDM ?
PNS...any update on the O/S this week?
Isn't ARCA known for shorting?
The dilutor VNDM is sitting at .05. Seems dilution is on hold for a moment.
Need to find out why i can't see ARCA with TD Ameritrade. Wonder if i need a margin account to see it.
Buy back will never happen.
The opposite appears to be in the future.
Look on level 2 and you can see VNDM on the ask at .05. Seems a round of dilution is in the cards if the SP makes it up that high.
I called the main phone number from Alternativ Clinical Trials web page. It was disconnected. I did not try the cell #(listed on website). Don't want to bother Tami.
I did a quick search for the company name on LinkedIn and found several employees whose employments ended in 2015. There were some other names i was not able to view their profile. I did not see any current employees of Alternativ.
Maybe this place downsized a while ago.
IR emailed me with the reply ..."the company is planning to host a conference call on the 23rd to provide a business update."
You are correct about 2Q ER. i have not read it but we were not expecting great news from that. Hopefully the conference call will provide the good news we are waiting for.
Good point about the new software platform.
People are not remembering about that future revenue. They keep looking in the rearview mirror.
Please elaborate
Don't get excited about that yet. Last week Form 4 was posted only on Monday and late Friday (hrs after market close).
I would only start to say hmmmm if you don't see one by next Friday (and one is not posted between now and then).
Aaahh...mystery solved.
I do not see ARCA with TD Ameritrade. I do not know why, but you just helped me confirm this.
I often wondered what PNS was seeing with his past rants about. <bleeping> ARCA.
Now i need to find out why ARCA is not visible with TDA.
How strange that TDA is not showing it.
What is the MM code?
I don't see that with my TDA.
Right now Bid is .025
Ask .0284
Is that .0269 appearing and disappearing?
Anybody know when is ER?
IR could not give me a firm date and time last week.
Maybe a buyout news of ICT-107 (would be great) is being combined with ER?
Now they have 2 Investor Relations employees and a Marketing person.
It appears the days of silence are soon coming to an end.
The unknown is are they getting ready to market "good" news to the world?
VNDM sitting at .05.
Not looking to dilute at low SP today.
The person, Ken, that responded to you is now listed on Endonovo LinkedIn page as the VP of Investor Relations. He is based in Pittsburgh area.
Why does ENDV now have Steve as "Sr VP of investor relations" and Ken as "VP of investor relations"? Why do they now need 2 Investor Relations "executives"?
They have 2 employees based in Pittsburgh area. Ken and Gary (marketing)....and have secretly...or had...Teri from Alternativ Clinical Trials. Need to know why her voicemail message is on an Endonovo phone # in Pittsburgh.
Something brewing in Pittsburgh while Alan and Michael are based in LA.
Hmmm.
Form 10-Q Discussion.
I am surprised nobody is mentioning anything about the 10-Q.
Not much to discuss other than dilution of shares it seems.
Consulting services have increased with the payments coming from equity shares. I suppose these consultants might be the "new" employees (VP, Marketing Mgr) and who knows what else.
The Consulting expense increased from $35K in Q1 to $148K in Q2...all paid via common shares issued.
Or their payment is coming from stock options.
Something new that was not on the 1Q 10-Q is the mention of Stock Options.
Stock Options were granted to independent contractors exercisable into up to 19,250,000 shares of common stock. They have an exercise price of $0.054/share
None were exercised in Q2. They were most likely issued towards the end of the quarter. It seems that's when the "new" employees (or should we call them "contractors"?) showed up on the LinkedIn page.
Tks. Those must have been posted late on Friday. Definitely after my post here, because i had checked before making my last observation.
You finally get a person on the phone from one of the PA numbers?
It is not a real job posting...according to Endonovo. It was posted 6 months ago.
I hope ICLD reads your message as homework this weekend for updating their corporate update to the shareholders <grin>
Ask about Gary, the Marketing Manager, listed on the company Endonovo LinkedIn page. Gary is in PA, not CA.
So now they have a Marketing Mgr, have or had a VP located in PA, and suspicious telemarketing employment ad in PA.
PAa appears to be where they will do the clinical trial with patients.
And still no Form 4 posted today. Last one was on Monday.
They appear to be getting ready to PR a material event...IMO
Thanks for the update.
Lots of dumping in the 2s today. All the new names of yesterday are not around today.
Seems the breakout board attracted some flippers and had no patience to hold?
No Form 4 since Monday.
How long do they have to post the Form 4 publicly?
Mann's last published purchase was Friday of last week.
If he bought Monday...has till Wed. to report to SEC. What is the deadline of that purchase to be posted to the public?
This might be the longest span of days without seeing a Form 4.